HDAC5 inactivates CYR61-regulated CD31/mTOR axis to prevent the occurrence of preeclampsia
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Our study was to pinpoint the significance of histone deacetylase 5 (HDAC5) affecting the pathogenesis of preeclampsia (PE) via CD31/mammalian target of rapamycin (mTOR) axis by regulating cysteine-rich angiogenic inducer 61 (CYR61). Expression of HDAC5, CYR61, and CD31/mTOR in placental tissues of patients with PE and trophoblast cells HTR-8/SVneo cells was determined first followed by their interaction analysis. Following different transfection, the significance of HDAC5 in cell functions was assayed in relation to CYR61 and CD31/mTOR. An in vivo PE mouse model was constructed for further validation. The clinical tissue and in vitro cell experimentations discovered that HDAC5 was downregulated in placental tissues of PE patients and trophoblast cells, while CYR61, CD31, mTOR, and p-mTOR displayed upregulation. After overexpression of HDAC5, trophoblast cell functions were enhanced. HDAC5 reduced the acetylation enrichment of H3K27 to inhibit the expression of CYR61. Furthermore, CYR61 promoted the activation of CD31/mTOR axis, thereby inhibiting HTR-8/SVneo cell functions. The in vivo rat model confirmed the above alterations. Taken together, HDAC5 contributes to downregulation of CYR61 through histone deacetylation, inactivating CD31/mTOR axis, which prevents the occurrence and development of PE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:390 |
|---|---|
| Enthalten in: |
Cell and tissue research - 390(2022), 2 vom: 28. Nov., Seite 281-292 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Peiyue [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.11.2022 Date Revised 04.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00441-022-03652-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344203409 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344203409 | ||
| 003 | DE-627 | ||
| 005 | 20231226022223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00441-022-03652-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344203409 | ||
| 035 | |a (NLM)35900603 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Peiyue |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HDAC5 inactivates CYR61-regulated CD31/mTOR axis to prevent the occurrence of preeclampsia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.11.2022 | ||
| 500 | |a Date Revised 04.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a Our study was to pinpoint the significance of histone deacetylase 5 (HDAC5) affecting the pathogenesis of preeclampsia (PE) via CD31/mammalian target of rapamycin (mTOR) axis by regulating cysteine-rich angiogenic inducer 61 (CYR61). Expression of HDAC5, CYR61, and CD31/mTOR in placental tissues of patients with PE and trophoblast cells HTR-8/SVneo cells was determined first followed by their interaction analysis. Following different transfection, the significance of HDAC5 in cell functions was assayed in relation to CYR61 and CD31/mTOR. An in vivo PE mouse model was constructed for further validation. The clinical tissue and in vitro cell experimentations discovered that HDAC5 was downregulated in placental tissues of PE patients and trophoblast cells, while CYR61, CD31, mTOR, and p-mTOR displayed upregulation. After overexpression of HDAC5, trophoblast cell functions were enhanced. HDAC5 reduced the acetylation enrichment of H3K27 to inhibit the expression of CYR61. Furthermore, CYR61 promoted the activation of CD31/mTOR axis, thereby inhibiting HTR-8/SVneo cell functions. The in vivo rat model confirmed the above alterations. Taken together, HDAC5 contributes to downregulation of CYR61 through histone deacetylation, inactivating CD31/mTOR axis, which prevents the occurrence and development of PE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD31 | |
| 650 | 4 | |a CYR61 | |
| 650 | 4 | |a HDAC5 | |
| 650 | 4 | |a Preeclampsia | |
| 650 | 4 | |a Trophoblast cells | |
| 650 | 4 | |a mTOR | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Histone Deacetylases |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a MTOR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 650 | 7 | |a HDAC5 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 650 | 7 | |a Hdac5 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 650 | 7 | |a mTOR protein, rat |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 650 | 7 | |a Hdac5 protein, rat |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 700 | 1 | |a Ying, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhi |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Ruoan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jinling |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mengmeng |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiaofu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xiaojun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell and tissue research |d 1974 |g 390(2022), 2 vom: 28. Nov., Seite 281-292 |w (DE-627)NLM000028681 |x 1432-0878 |7 nnns |
| 773 | 1 | 8 | |g volume:390 |g year:2022 |g number:2 |g day:28 |g month:11 |g pages:281-292 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00441-022-03652-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 390 |j 2022 |e 2 |b 28 |c 11 |h 281-292 | ||